Memantine hydrochloride is a raw material. It should be prescribed by experienced doctors in the diagnosis and treatment of Alzheimer's dementia and guided by patients. Treatment can only begin when there are caregivers around the patient who regularly supervise the patient's medication. Dementia should be diagnosed in accordance with current diagnostic criteria and guidelines.
Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions
Memantine is clinically used for the treatment of moderate to severe senile dementia and parkinsonism syndrome. It is a new type of anti-senile dementia drug and can be used for the treatment of moderate to severe senile dementia.
Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.
Memantine has been associated with a modest improvement; with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease. There does not appear to be any benefit in mild disease.
Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. The UK National Institute of Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia. Effects in autism are unclear. Recent scientific journal reports are showing guarded promise with severe obsessive compulsive disorder.
Ni havas multajn altkvalitajn fabrikojn kun profunda kunlaboro, kiuj povas provizi al vi altkvalitajn produktojn kaj konkurencivajn prezojn. Kaj ni ankaŭ povas doni rabatojn por pograndaj aĉetoj. Kaj ni kunlaboras kun multaj profesiaj ekspedaj kompanioj, povas liveri produktojn sekure kaj glate al viaj manoj. Livera tempo estas ĉirkaŭ 3-20 tagoj post konfirmo de pago.
Ero |
Requirements |
Test Results |
appearance |
White or almost white crystalline powder |
White crystalline powder |
Identigo |
IR |
Comply |
Related substance |
1-methyladamantane ≤0.3% 1,3,5 -trimethyladamantane ≤0.3% Unknow impuritiy ≤0.1% Total impurity ≤0.5% |
0.13% 0.14% <0.1% <0.4% |
Restaĵo ĉe ekbruligo |
≤0.1% |
0.06% |
Heavy matal |
≤10ppm |
<10ppm |
Perdo dum sekiĝo |
≤0.5% |
0.29% |
Testo |
98.5-101.0% |
99.13% |
Residual Solvents |
Ethyl Acetat: ≤0.5% Ethanol: ≤0.5% |
0.08% 0.12% |
PH |
4.5-5.5 |
5.3 |
Microbial Limits |
Max 5*102 aerobes and fungl per 1g E. Coli: Negative Salmonella: Negative
|
Pass |
Size of distributed particles |
Pass 100μ m |
Konformas |
Konkludo |
Meet the requirements |
Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions
Memantine HCl is the HCl form of Memantine. Memantine is a well- known neuroprotective drug used for the treatment of Alzheimer's disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European.
The development of Alzheimer's disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity.
Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs).
Memantine is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington's disease, ALS and movement disorders, among other.
1. Ĉu vi estas fabriko aŭ komerca kompanio?
Ni estas kompanio integranta industrion kaj komercon, provizanta unu-haltan servon. OEM povus esti akceptita.
2. Ĉu vi provizas specimenojn? Ĉu ĝi estas senpaga aŭ kroma?
Senpagaj specimenoj.La ŝarĝkotizo de la specimeno devas esti pagita de via flanko.
3. Ĉu vi havas atestojn rilatajn al kvalito-kontrolo?
Atestilo ISO 9001:2008 por certigi kvaliton.
4. Kion mi donu por ricevi citaĵon?
Bonvolu informi nin pri la produkta tipo, kiun vi bezonas, menda kvanto, adreso kaj specifaj postuloj. La citaĵo estos farita por via referenco ĝustatempe.
5. Kian pagan metodon vi preferas? Kiaj terminoj estas akceptataj?
Akceptitaj Liveraj Kondiĉoj: FOB, CFR, CIF, EXW;
Akceptita Paga Monero:USD;
Akceptita Paga Tipo: T/T,Western Union; Paypal, Komerca Asekuro.
Parola lingvo: la angla.
Kategorioj de produktoj